New agents in the treatment of childhood leukemias and myelodysplastic syndromes
- 47 Downloads
Relapsed or refractory leukemia remains the most common therapeutic problem in pediatric oncology. Particularly challenging is the patient who has recurrence following a stem cell transplant. Insights into the molecular pathogenesis of the leukemias have produced an array of new agents. These new agents will be more selective in hitting their targets, and so their use will be more narrowly defined than with classical cytotoxic drugs. These new agents include all-trans retinoic acid, gemtuzumab ozogamicin, imatinib mesylate, rituximab, and a bevy of signal transduction inhibitors and therapeutic monoclonal antibodies. Other new agents, such as liposomal daunorubicin, PEG-asparaginase, or clofarabine, represent chemical modifications of established antileukemic drugs. Increasingly, molecular profiling will be used to guide the development and application of new drugs.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 3.Wells RJ, Adams MT, Alonzo TA, et al.: Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children’s Cancer Group Study 2951. J Clin Oncol 2003, 21:2940–2947. Demonstrates excellent salvage rate in children and provides a gold standard for alternative regimens.PubMedCrossRefGoogle Scholar
- 6.Cheson BD, Bennett JM, Kopecky KJ, et al.: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003, 21:4642–4649. Provides a critical analysis and prescription for the design and interpretation of clinical trials in leukemia.PubMedCrossRefGoogle Scholar
- 9.Liu Yin JA, Wheatley K, Rees JK, Burnett AK: Comparison of "sequential" versus "standard" chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/ relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br J Haematol 2001, 113:713–726.PubMedCrossRefGoogle Scholar
- 17.Druker BJ, Talpaz M, Resta DJ, et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031–1037. The first report of efficacy of imatinib mesylate, heralding the signal transduction inhibitor therapeutic era.PubMedCrossRefGoogle Scholar
- 32.Sievers EL, Larson RA, Stadtmauer EA, et al.: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001, 19:3244–3254. Phase II study demonstrated 30% response rate for gemtuzumab ozogamicin in adults with their first untreated relapse.PubMedGoogle Scholar